4.8 Article

LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin

Journal

CANCER CELL
Volume 23, Issue 2, Pages 143-158

Publisher

CELL PRESS
DOI: 10.1016/j.ccr.2012.12.008

Keywords

-

Funding

  1. National Center for Advancing Translational Sciences through UCLA CTSI grant [UL1TR000124, KL2TR000122]
  2. National Institutes of Health [R01 DK080425, P01CA120964]
  3. American Cancer Society Research Scholar Award [RSG-07-210-01-MGO]
  4. Salk CCSG [P30 CA014195]
  5. Samuel Waxman Cancer Research Foundation
  6. [S10RR026744]
  7. [T32 CA009370]

Ask authors/readers for more resources

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in similar to 20% of non-small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival. This study suggests phenformin as a cancer metabolism-based therapeutic to selectively target LKB1-deficient tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available